In a groundbreaking collaboration that promises to reshape the future of medicine, Factor Bioscience and Eterna Therapeutics have announced an exclusive license agreement to accelerate the development of stem cell-based therapies for oncology, autoimmune disorders, and rare diseases.
The agreement is centered around the utilization of Factor’s proprietary induced pluripotent stem cell (iPSC) technologies, which will allow Eterna to develop cutting-edge cell therapy candidates.
Under this partnership, Eterna gains exclusive rights to develop and market products using iPSC-derived mesenchymal stem cells (iMSCs), which are genetically engineered to express specific cytokines for targeted therapies.
This collaboration is set to provide innovative treatments, particularly for solid tumors, autoimmune conditions, and genetically rare diseases.
Eterna’s CEO, Sanjeev Luther, emphasized the potential of these therapies to address difficult-to-treat diseases like triple-negative breast cancer and platinum-resistant ovarian cancer, while Factor Bioscience will receive milestone payments and royalties as the products advance.
The use of gene-editing and cell reprogramming technologies marks a significant leap toward more effective, off-the-shelf cell therapies that could transform patient care globally.
With the expertise and technologies shared between these two companies, this collaboration aims to accelerate the path to IND filings and eventual commercialization.
This exciting development underscores the power of stem cell research and innovation in crafting treatments that could save millions of lives.
Stay tuned for more advancements as Factor Bioscience and Eterna Therapeutics bring these promising therapies closer to reality.